【摘要】 目的观察重组人干扰素α-2b注射液治疗丙型肝炎的临床疗效。方法将我院2012年1月至2013年1月期间收治的80例丙型肝炎患者随机分为观察组40例和对照组40例。对照组患者在常规治疗的基础上行阿德福韦酯治疗,观察者患者在常规治疗的基础上行重组人干扰素α-2b注射液治疗。观察2组患者治疗前后的肝功能指标变化情况,统计2组患者治疗期间及治疗后HCV-RNA的阴转率及不良反应发生率。结果治疗后,观察组患者肝功能指标TBIL、ALT、AST平均水平明显低于对照组,2组比较,差异具有统计学意义(P<0.05)。治疗12周、24周及治疗后24周,观察组患者HCV-RNA的阴转率均大于对照组(P<0.05)。观察组患者不良反应的总发生率为50%,对照组为42.5%,2组比较,差异无统计学意义(P>0.05)。且2组患者均无对治疗不能耐受而停药者。结论重组人干扰素α-2b注射液治疗丙型肝炎的临床疗效显著,且安全性较好,值得临床推广与应用。更多还原

【Abstract】 Objective To observe the clinical curative effect of interferon α-2b injection for the treatment of hepatitis C.Methods 80 cases of hepatitis C patients in our hospital from 2012 January to 2013 January were randomly divided into the observation group( 40 cases) and control group with 40 cases. On the same basis treatment,the control were added Adefovir dipivoxil,the observer patients added α-2b injection. To observe the changes of liver function indexes in the 2 groups before and after treatment. Results The observation group patients liver function indexes of TBIL,ALT,AST mean levels were significantly lower than the control group( P<0. 05). After 12,24 weeks,HCV-RNA negative conversion rate of the observation group were higher than those in the control group( P<0. 05). Conclusion The clinical efficacy of interferon alfa-2b injection for the treatment of hepatitis C were significant and safety.更多还原